Hydromorphone Hydrochloride is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 10, 2043. Details of Hydromorphone Hydrochloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12653820 | Hydromorphone Formulations For Multi-Dose Products |
Jan, 2043
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Hydromorphone Hydrochloride is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Hydromorphone Hydrochloride's family patents as well as insights into
ongoing legal events
on those patents.
Hydromorphone Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Hydromorphone Hydrochloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 10, 2043 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Hydromorphone Hydrochloride Generic API suppliers:
Hydromorphone Hydrochloride is the generic name for the brand Hydromorphone Hydrochloride. 17 different companies have already filed for the generic of Hydromorphone Hydrochloride, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Hydromorphone Hydrochloride's generic
Alternative Brands for Hydromorphone Hydrochloride
There are several other brand drugs using the same active ingredient (Hydromorphone Hydrochloride) as Hydromorphone Hydrochloride. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Fresenius Kabi Usa |
| ||
| Purdue Pharma Lp |
| ||
| Rhodes Pharms |
| ||
| Specgx Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydromorphone Hydrochloride, Hydromorphone Hydrochloride's active ingredient. Check the complete list of approved generic manufacturers for Hydromorphone Hydrochloride
About Hydromorphone Hydrochloride
Hydromorphone Hydrochloride is a drug owned by Hikma Pharmaceuticals Usa Inc. Hydromorphone Hydrochloride uses Hydromorphone Hydrochloride as an active ingredient. Hydromorphone Hydrochloride was launched by Hikma in 2023.
Approval Date:
Hydromorphone Hydrochloride was approved by FDA for market use on 14 December, 2023.
Active Ingredient:
Hydromorphone Hydrochloride uses Hydromorphone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Hydromorphone Hydrochloride ingredient
Dosage:
Hydromorphone Hydrochloride is available in solution form for intramuscular, intravenous, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG/20ML (2MG/ML) | SOLUTION | Prescription | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS |